Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.

Hilhorst, Riet; van den Berg, Adrienne; Boender, Piet; van Wezel, Tom; Kievits, Tim; de Wijn, Rik; Ruijtenbeek, Rob; Corver, Willem E; Morreau, Hans

Hilhorst, Riet; van den Berg, Adrienne; Boender, Piet; van Wezel, Tom; Kievits, Tim; de Wijn, Rik; Ruijtenbeek, Rob; Corver, Willem E; Morreau, Hans.

Afiliação

Hilhorst R; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands.
van den Berg A; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands.
Boender P; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands.
van Wezel T; Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Kievits T; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands.
de Wijn R; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands.
Ruijtenbeek R; PamGene International BV, 5211 HH 's-Hertogenbosch, The Netherlands.
Corver WE; Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Morreau H; Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Cancers (Basel) ; 15(18)2023 Sep 08.

Article em En | MEDLINE | ID: mdl-37760447

Palavras-chave

BRAF mutation; dabrafenib; kinase activity profiling; peptide microarray; thyroid

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google